Fiscal Year 2019 Department of Defense Amyotrophic Lateral Sclerosis Research Program Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
Therapeutic Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-19-ALSRP-TDA	Independent investigators at all levels	 Pre-Application is required; Full Application submission is by invitation only Supports post-discovery, preclinical development of therapeutics for ALS Preliminary data, including identity and purity of an identified bioactive compound(s), are required Therapeutically Relevant Marker Option available Collaboration with industry is encouraged Clinical trials are not allowed 	Maximum funding of \$1.0 million for direct costs (plus indirect costs); \$1.25 million for direct costs (plus indirect costs) for applications including the Therapeutically Relevant Marker Option Maximum period of performance is 2 years	Pre-Application: March 22, 2019 5:00 p.m. Eastern time Preproposal is required; application submission is by invitation only. Application: July 25, 2019 11:59 p.m. Eastern Time
Therapeutic Idea Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-19-ALSRP-TIA	Independent investigators at all levels	 Pre-Application is required; Full Application submission is by invitation only Supports screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development Preliminary data are not required Not intended to support projects focusing on the pathophysiology of ALS 	 Maximum funding of \$500,000 for direct costs (plus indirect costs) Maximum period of performance is 2 years 	Pre-Application: March 22, 2019 5:00 p.m. Eastern time Preproposal is required; application submission is by invitation only. Application: July 25, 2019 11:59 p.m. Eastern Time